Rhythm Pharmaceuticals (RYTM) closed at $112.28 on November 6, 2026, up 6.9% from the previous close, on volume of 4,856,689 shares (30-day average 1,278,585).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 30, 2026 | Call Spread | 20-Nov-2695 : 105 C | 304 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Key deals this week: PANW, META, OGI, CRM and more
Seeking Alpha News (Sat, 7-Nov 3:15 PM ET)
Rhythm Pharmaceuticals gains on report of additional bidder
Seeking Alpha News (Fri, 6-Nov 11:06 AM ET)
Rhythm Pharmaceuticals’ Strong Imcivree Launch and Pipeline Progress Support $130 Price Target
TipRanks (Fri, 6-Nov 2:16 AM ET)
Rhythm Pharmaceuticals (RYTM) Receives a Rating Update from a Top Analyst
TipRanks (Thu, 5-Nov 7:16 AM ET)
Analysts Offer Insights on Healthcare Companies: Opko Health (OPK) and Rhythm Pharmaceuticals (RYTM)
TipRanks (Thu, 5-Nov 6:50 AM ET)
TipRanks (Thu, 5-Nov 3:50 AM ET)
TipRanks (Thu, 5-Nov 1:00 AM ET)
Rhythm Pharmaceuticals jumps on report AstraZeneca made $10B bid
Seeking Alpha News (Wed, 4-Nov 4:13 PM ET)
TipRanks (Wed, 4-Nov 8:30 AM ET)
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Rhythm Pharmaceuticals trades on the NASDAQ stock market under the symbol RYTM.
As of November 6, 2026, RYTM stock price climbed to $112.28 with 4,856,689 million shares trading.
RYTM has a beta of 1.03, meaning it tends to be more sensitive to market movements. RYTM has a correlation of 0.07 to the broad based SPY ETF.
RYTM has a market cap of $7.78 billion. This is considered a Mid Cap stock.
Last quarter Rhythm Pharmaceuticals reported $92 million in Revenue and -$.61 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.12.
In the last 3 years, RYTM traded as high as $122.20 and as low as $23.83.
The top ETF exchange traded funds that RYTM belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.
RYTM has outperformed the market in the last year with a price return of +14.0% while the SPY ETF gained +10.8%. RYTM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +0.2% and +25.8%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
RYTM support price is $101.68 and resistance is $108.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RYTM shares will trade within this expected range on the day.
